检索结果-南通市图书馆

metabolic-associated fatty liver disease and sarcopenia:A double whammy

World Journal of Hepatology 2024年第2期16卷 152-163页

作者： Aditya Viswanath Sherouk Fouda Cornelius James Fernandez Joseph M Pappachan School of Medicine Leicester UniversityLeicester LE17RHUnited Kingdom School of Health and Biomedical Sciences Rmit UniversityMelbourne VICAustralia Department of Endocrinology and Metabolism Pilgrim HospitalUnited Lincolnshire Hospitals NHS TrustBoston PE219QSUnited Kingdom Department of Endocrinology and Metabolism Lancashire Teaching Hospitals NHS TrustPreston PR29HTUnited Kingdom Faculty of Science Manchester Metropolitan UniversityManchester M156BHUnited Kingdom Faculty of Biology Medicine and HealthThe University of ManchesterManchester M139PLUnited Kingdom

The prevalence of metabolic-associated fatty liver disease(MAFLD)has increased substantially in recent years because of the global obesity ***,now recognized as the number one cause of chronic liver disease in the world,not only increases liver-related morbidity and mortality among sufferers but also worsens the complications associated with other comorbid conditions such as cardiovascular disease,type 2 diabetes mellitus,obstructive sleep apnoea,lipid disorders and *** the interplay between MAFLD and these comorbidities is important to design optimal therapeutic *** can be either part of the disease process that results in MAFLD(e.g.,obesity or adiposity)or a consequence of MAFLD,especially in the advanced stages such as fibrosis and *** can also worsen MAFLD by reducing exercise capacity and by the production of various muscle-related chemical ***,it is crucial to thoroughly understand how we deal with these diseases,especially when they *** explore the pathobiological interlinks between MAFLD and sarcopenia in this comprehensive clinical update review article and propose evidence-based therapeutic strategies to enhance patient care.

关键词： metabolic-associated fatty liver disease Sarcopenia Sarcopenic obesity Lean metabolic-associated fatty liver disease Cardiovascular disease liver-muscle axis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

metabolic-associated fatty liver disease:New nomenclature and approach with hot debate

引用

World Journal of Hepatology 2023年第2期15卷 123-128页

作者： Yasser Fouad Department of Gastroenterology and Endemic Medicine Minia UniversityMinia 19111Egypt

An international panel recently proposed an update to the terminology and diagnostic criteria for fatty liver *** experts proposed a change in the nomenclature from non-alcoholic fatty liver disease(NAFLD)to metabolic(dysfunction)-associated fatty liver disease(MAFLD).This single-letter change,we believe,heralds the dawn of a new era in clinical practice and in clinical and basic research as *** new nomenclature with the easily applicable approach has stimulated the enthusiasm of the researchers worldwide,resulting in a large number of publications over the past two *** recent studies have provided tremendous evidence of the superiority of the MAFLD criteria over the NAFLD *** studies in different geographic areas of the world including the United States,Europe,and Asia on a large number of patients proved that the utility of MAFLD criteria was higher than that of the NAFLD criteria in different aspects of fatty liver ***,many societies,physician and nurse groups,health stakeholders,representatives of regulatory sciences,and others endorsed the new *** we highlight the endorsement of the new name by different societies and groups and the outcome of different studies on the new nomenclature in addition to a short discussion of the debate by some experts.

关键词： Non-alcoholic fatty liver disease metabolic-associated fatty liver disease liver disease Fibrosis New nomenclature Redefinition

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Alcohol and metabolic-associated fatty liver disease

引用

Journal of Clinical and Translational Hepatology 2021年第5期9卷 719-730页

作者： Fu-Rong Sun Bing-Yuan Wang Department of Elderly Gastroenterology The First Hospital of China Medical UniversityShenyangLiaoningChina

The diagnosis of metabolic-associated fatty liver disease is based on the detection of liver steatosis together with the presence of metabolic *** to this new definition,the diagnosis of metabolic-associated fatty liver disease is independent of the amount of alcohol ***,alcohol and its metabolites have various effects on metabolicassociated abnormalities during the process of alcohol *** have shown improved metabolic function in light to moderate alcohol *** are several studies focusing on the role of light to moderate alcohol intake on metabolic ***,the results from studies are diverse,and the conclusions are often *** review systematically discusses the effects of alcohol consumption,focusing on light to moderate alcohol consumption,obesity,lipid and glucose metabolism,and blood pressure.

关键词： Alcohol metabolic-associated fatty liver disease Obesity Insulin resistance Hypertension

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Management of metabolic-associated fatty liver disease: The diabetology perspective

引用

World Journal of Gastroenterology 2023年第1期29卷 126-143页

作者： Mohammad Sadiq Jeeyavudeen Shahanas K A Khan Sherouk Fouda Joseph M Pappachan Department of Endocrinology and Metabolism University Hospitals of EdinburghEdinburgh EH42XUUnited Kingdom Department of Endocrinology and Metabolism Lancashire Teaching Hospitals NHS TrustPreston PR29HTUnited Kingdom School of Health and Biomedical Sciences RMIT UniversityMelbourneVIC 3046Australia Faculty of Science Manchester Metropolitan UniversityManchester M156BHUnited Kingdom Faculty of Biology University of ManchesterManchester M139PLUnited Kingdom

The metabolic syndrome as a consequence of the obesity pandemic resulted in a substantial increase in the prevalence of metabolic-associated fatty live disease(MAFLD)and type 2 diabetes mellitus(T2DM).Because of the similarity in pathobiology shared between T2DM and MAFLD,both disorders coexist in many patients and may potentiate the disease-related outcomes with rapid progression and increased complications of the individual *** fact,awareness about this coexistence and the risk of complications are often overlooked by both hepatologists and *** of these individual disorders in a patient should be addressed wholistically using an appropriate multidisciplinary team approach involving both the specialists and,when necessary,liaising with dieticians and *** comprehensive review is to compile the current evidence from a diabetologist's perspective on MAFLD and T2DM and to suggest optimal management strategies.

关键词： metabolic syndrome metabolic-associated fatty liver disease Type 2 diabetes mellitus Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Diabetology perspective Obesity

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Association between Serum Ferritin Levels and metabolic-associated fatty liver disease in Adults:a Cross-sectional Study Based on the NHANES

引用

Current Medical Science 2024年第3期44卷 494-502页

作者： Jiang-hui LI Xue-yao MA Yun YI Lu-rao LI Zhi-yong XU Ying CHANG Department of Gastroenterology Zhongnan Hospital of Wuhan UniversityWuhan430071China Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal diseases Wuhan430071China Endoscopy Center The People’s Hospital of YingshanHuanggang438799China

Objective Ferritin,initially acting as an iron-storage protein,was found to be associated with metabolic *** study was designed to investigate the association between serum ferritin and metabolic-associated fatty liver disease(MAFLD)using data from the National Health and Nutrition Examination Survey(NHANES)of the United State of *** A cross-sectional study was conducted,enrolling a total of 2145 participants from the NHANES in the 2017–2018 *** steatosis and liver fibrosis were assessed by ultrasound images and several non-invasive *** regression analysis was conducted to determine the associations between serum ferritin concentration and MAFLD and liver *** The analysis revealed that participants with higher serum ferritin levels(Q3 and Q4 groups)had a higher prevalence of MAFLD than those with the lowest serum ferritin levels[Q3 vs.Q1:OR=2.17(1.33,3.53),Pfatty liver index(FLI);Q4 vs.Q1:OR=3.13(1.91,5.13),Pliver fibrosis[Q4 vs.Q1:OR=2.59(1.19,5.62),Pliver stiffness measurement;OR=5.06(1.12,22.94),Passociated with a higher prevalence of MAFLD and advanced liver fibrosis in *** serum ferritin levels combined with diabetes are important risk factors for liver fibrosis.

关键词： serum ferritin liver fibrosis metabolic-associated fatty liver disease National Health and Nutrition Examination Survey

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in metabolic-associated fatty liver disease

引用

Journal of Clinical and Translational Hepatology 2022年第4期10卷 589-594页

作者： Xiaoning Chen George Boon-Bee Goh Jiaofeng Huang Yinlian Wu Mingfang Wang Rahul Kumar Su Lin Yueyong Zhu Department of Hepatology Hepatology Research InstituteThe First Affiliated Hospital of Fujian Medical UniversityFu-zhouFujianChina Department of Gastroenterology&Hepatology Singapore General HospitalSingapore Duke-NUS Medical School Singapore Department of Gastroenterology and Hepatology Duke-NUS Academic Medical CentreChangi General HospitalSingapore

Background and Aims:metabolic-associated fatty liver disease(MAFLD)is a newly proposed terminology from 2020;yet,the applicability of conventional noninvasive fi-brosis models is still unknown for *** aimed to evaluate the performance of conventional noninvasive fibrosis scores in ***:The NHANES 2017-2018 datasets were used to compare the performances of different non-invasive fibrosis scores in MAFLD,including the aspartate aminotransferase(AST)to platelet ratio index(APRI),body mass index(BMI)-AST/alanine aminotransferase(ALT)ratio and diabetes score(BARD),fibrosis-4 index(FIB-4),and NAFLD fibrosis score(NFS).Moreover,Asian patients with biopsy-proven MAFLD were enrolled to further validate the ***:A total of 2,622 participants in the Na-tional Health and Nutrition Examination Survey(NHANES)cohort and 293 patients with MAFLD in the Asian cohort were *** in the Asian cohort had a lower BMI and higher liver enzymes(pliver enzymes when NFS is *** efficient noninvasive fibrosis scor-ing systems are highly required for patients with MAFLD.

关键词： FIB-4 metabolic-associated fatty liver disease liver fibrosis NFS Noninvasive fibrosis scores

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Elafibranor:A promising treatment for alcoholic liver disease,metabolic-associated fatty liver disease,and cholestatic liver disease

引用

World Journal of Gastroenterology 2024年第40期30卷 4393-4398页

作者： Hang Zhang Xuan Dong Lei Zhu Fu-Shan Tang Department of Clinical Pharmacy Key Laboratory of Basic Pharmacology of Guizhou Province and School of PharmacyZunyi Medical UniversityZunyi 563006Guizhou ProvinceChina Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education Zunyi Medical UniversityZunyi 563006Guizhou ProvinceChina Key Laboratory of Clinical Pharmacy in Zunyi City Zunyi Medical UniversityZunyi 563006Guizhou ProvinceChina

liver diseases pose a significant threat to human *** effective therapeutic agents exist for some liver diseases,there remains a critical need for advancements in research to address the gaps in treatment options and improve patient *** article reviews the assessment of Elafibranor's effects on liver fibrosis and intestinal barrier function in a mouse model of alcoholic liver disease(ALD),as reported by Koizumi et al in the World Journal of *** summarize the impact and mechanisms of Elafibranor on ALD,metabolic-associated fatty liver disease,and cholestatic liver disease based on current *** also explore its potential as a dual agonist of PPARα/δ,which is undergoing Phase III clinical trials for metabolic-associated *** goal is to stimulate further investigation into Elafibranor's use for preventing and treating these liver diseases and to provide insights for its clinical application.

关键词： Elafibranor Peroxisome proliferator activated receptor liver fibrosis Alcoholic liver disease metabolic-associated fatty liver disease metabolic-associated steatohepatitis Cholestatic liver disease Primary biliary cholangitis liver diseases

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Gut Microbiota in metabolic-associated fatty liver disease and in Other Chronic metabolic diseases

引用

Journal of Clinical and Translational Hepatology 2021年第2期9卷 227-238页

作者： Winston Hernández-Ceballos Jacqueline Cordova-Gallardo Nahum Mendez-Sanchez Plan of Combined Studies in Medicine(PECEM-MD/PhD) Faculty of MedicineNational Autonomous University of MexicoMexico CityMexico Department of Hepatology Service of Surgery and Obesity ClinicGeneral Hospital“Dr.Manuel Gea González”Mexico CityMexico Faculty of Medicine.National Autonomous University of Mexico Mexico CityMexico liver Research Unit Medica Sur Clinic&FoundationMexico CityMexico

The gut microbiome plays a key role in the health-disease balance in the human *** its composition is unique for each person and tends to remain stable throughout lifetime,it has been shown that certain bacterial patterns may be determining factors in the onset of certain chronic metabolic diseases,such as type 2 diabetes mellitus(T2DM),obesity,metabolic-associated fatty liver disease(MAFLD),and metabolic *** gut-liver axis embodies the close relationship between the gut and the liver;disturbance of the normal gut microbiota,also known as dysbiosis,may lead to a cascade of mechanisms that modify the epithelial properties and facilitate bacterial *** of gut microbiota is fundamental to maintaining gut integrity,as well as the bile acids *** the present review,we summarize the current knowledge regarding the microbiota,bile acids composition and their association with MAFLD,obesity,T2DM and metabolic syndrome.

关键词： metabolic-associated fatty liver disease metabolic-associated steatohepatitis Gut microbiota Gut-liver axis Dysbiosis Bile acids

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Lipotoxic hepatocyte-derived exosomal miR-1297 promotes hepatic stellate cell activation through the PTEN signaling pathway in metabolic-associated fatty liver disease

引用

World Journal of Gastroenterology 2021年第14期27卷 1419-1434页

作者： Xin Luo Sheng-Zheng Luo Zi-Xin Xu Cui Zhou Zheng-Hong Li Xiao-Yan Zhou Ming-Yi Xu Department of Gastroenterology Shanghai General HospitalShanghai 200080China

BACKGROUND Exosomes play an important role in metabolic-associated fatty liver disease(MAFLD),but the mechanism by which exosomes participate in MAFLD still remain *** To figure out the function of lipotoxic exosomal miR-1297 in *** MicroRNA sequencing was used to detect differentially expressed miRNAs(DEmiR)in lipotoxic exosomes derived from primary *** tools were applied to analyze the target genes and pathways regulated by the *** real-time PCR(qPCR)was conducted for the verification of ***,western blot,immunofluorescence staining and ethynyl-20-deoxyuridine assay were used to evaluate the function of lipotoxic exosomal miR-1297 on hepatic stellate cells(LX2 cells).A luciferase reporter experiment was performed to confirm the relationship of miR-1297 and its target gene *** MicroRNA sequencing revealed that there were 61 exosomal DE-miRs(P2 from palmitic acid treated primary hepatocytes compared with the vehicle control ***-1297 was the most highly upregulated according to the microRNA *** tools showed a variety of target genes and pathways regulated by these DE-miRs were related to liver ***-1297 was overexpressed in exosomes derived from lipotoxic hepatocytes by *** promoting genes(α-SMA,PCNA)were altered in LX2 cells after miR-1297 overexpression or miR-1297-rich lipotoxic exosome incubation via qPCR and western blot *** staining and ethynyl-20-deoxyuridine staining demonstrated that the activation and proliferation of LX2 cells were also promoted after the above *** was found to be the target gene of miR-1297 and knocking down PTEN contributed to the activation and proliferation of LX2 cells via modulating the PI3K/AKT signaling *** miR-1297 was overexpressed in exosomes derived from lipotoxic *** lipotoxic hepatocyte-derived exosomal miR-1297 could promot

关键词： metabolic-associated fatty liver disease miRNA-1297 Exosome Hepatic stellate cell PTEN liver fibrosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Discrepancies between Nonalcoholic and metabolic-associated fatty liver disease by Multiple Steatosis Assessment

引用

Journal of Clinical and Translational Hepatology 2022年第6期10卷 1013-1026页

作者： Congxiang Shao Junzhao Ye Xin Li Yansong Lin Shiting Feng Bing Liao Wei Wang Xiaorong Gong Bihui Zhong Department of Gastroenterology of the First Affiliated Hospital Sun Yat-sen UniversityGuangzhouGuangdongChina Department of Gastroenterology Affiliated Dongguan People’s HospitalSouthern Medical University(Dongguan People’s Hospital)DongguanGuangdongChina Department of Radiology of the First Affiliated Hospital Sun Yat-sen Univer-sityGuangzhouGuangdongChina Department of Pathology of the First Affiliated Hospital Sun Yat-sen UniversityGuangzhouGuangdongChina Department of Medical Ultrasonics of the First Affiliated Hospital Sun Yat-sen UniversityGuangzhouGuangdongChina Department of Gastroenterology First Affiliated HospitalGuangzhou Medical UniversityGuangzhouGuangdongChina

Background and Aims:The redefinition of metabolic-as-sociated fatty liver disease(MAFLD)from nonalcoholic fat-ty liver disease(NAFLD)has caused a revolution in clinical practice,and the characteristics of patients with steatosis but not MAFLD remain *** aims were to compare the diagnosis rate of MAFLD in NAFLD using different steato-sis methods and explore the features of non-MAFLD-NAFLD and ***:A cross-sectional study enrolling consecutive individuals was conducted at three medical centers in southern China from January 2015 to September *** was evaluated by liver biopsy or magnetic resonance imaging-based proton density fat frac-tion(MRI-PDFF),ultrasound,controlled attenuation param-eter(CAP),and fatty liver index(FLI).Fibrosis was assessed by the NAFLD fibrosis score,transient elastography,or shear wave ***:The study enrolled 14,985 Chi-nese *** agreement of MAFLD and NAFLD diagnoses were 83%for FLI,95%for ultrasound,94%for both CAP and MRI-PDFF,and 95%for liver *** body mass index,blood pressure and lipid levels among non-MAFLD-NAFLD pa-tients were similar metabolic parameters(p>0.05 for all),but not the alanine aminotransferase and the proportion of pa-tients with insulin resistance,which were significantly higher in non-MAFLD-NAFLD with significant ***:The new MAFLD definition ruled out 5-17%of NAFLD *** and MAFLD-NAFLD involved more severe metabolic abnormalities than MAFLD and ***-MAFLD-NAFLD patients with significant fibrosis had more se-vere liver injury and increased glycemic dysregulation within the normal *** should be paid to its progression.

关键词： Controlled attenuation parameter fatty liver index liver biopsy metabolic-associated fatty liver disease Magnetic resonance imaging-based proton density fat fraction

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：